{"id":"continuous-docetaxel","safety":{"commonSideEffects":[{"rate":"75–90","effect":"Neutropenia"},{"rate":"5–10","effect":"Anemia"},{"rate":"5–10","effect":"Thrombocytopenia"},{"rate":"20–40","effect":"Peripheral neuropathy"},{"rate":"40–60","effect":"Fatigue"},{"rate":"30–50","effect":"Nausea/vomiting"},{"rate":"20–40","effect":"Diarrhea"},{"rate":"75–80","effect":"Alopecia"},{"rate":"2–5","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a semi-synthetic taxane derived from the Pacific yew tree that binds to microtubule-associated proteins and β-tubulin, promoting microtubule assembly and inhibiting disassembly. This leads to cell cycle arrest in the G2/M phase and apoptosis. The 'continuous' formulation refers to an extended or continuous dosing schedule rather than the standard intermittent regimen, potentially improving efficacy or tolerability.","oneSentence":"Continuous docetaxel is a taxane chemotherapy agent that stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:31.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT04633252","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-23","conditions":"Cancer Of Prostate, Prostate Neoplasms","enrollment":86},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT03390504","phase":"PHASE3","title":"A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-23","conditions":"Urothelial Cancer","enrollment":629},{"nctId":"NCT02973789","phase":"PHASE3","title":"Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)","status":"COMPLETED","sponsor":"NovoCure GmbH","startDate":"2016-12","conditions":"Nonsmall Cell Lung Cancer, NSCLC","enrollment":291},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":"Early Breast Cancer","enrollment":200},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06951646","phase":"PHASE2","title":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-10","conditions":"Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)","enrollment":70},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT06532032","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-23","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":12},{"nctId":"NCT07402473","phase":"PHASE2","title":"EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2026-03-01","conditions":"HER2-positive Early-stage Breast Cancer","enrollment":50},{"nctId":"NCT04577014","phase":"PHASE1, PHASE2","title":"Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-29","conditions":"Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma","enrollment":98},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT07400315","phase":"PHASE2","title":"First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT07393425","phase":"PHASE2","title":"Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-02","conditions":"HER2 + Breast Cancer","enrollment":50},{"nctId":"NCT05616624","phase":"PHASE1, PHASE2","title":"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-05","conditions":"Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer","enrollment":31},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT06484491","phase":"NA","title":"IMPT Dose Escalation for NSCLC (HyDose)","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-09-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":87},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT06123338","phase":"PHASE2","title":"A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-01","conditions":"Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation","enrollment":49},{"nctId":"NCT07366528","phase":"PHASE3","title":"Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-12-15","conditions":"Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer","enrollment":387},{"nctId":"NCT03456843","phase":"PHASE2","title":"Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2018-03-20","conditions":"Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":190},{"nctId":"NCT06967987","phase":"PHASE2","title":"Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b","status":"WITHDRAWN","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2026-01-01","conditions":"Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b","enrollment":""},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT07351565","phase":"PHASE1","title":"Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2026-01-10","conditions":"Non-Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT03556904","phase":"PHASE2","title":"FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2018-12-10","conditions":"Prostate Cancer","enrollment":14},{"nctId":"NCT07330050","phase":"PHASE2","title":"WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":31},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT04290793","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2020-03-01","conditions":"Breast Cancer","enrollment":113},{"nctId":"NCT07316686","phase":"PHASE1","title":"Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2026-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":18},{"nctId":"NCT07283848","phase":"PHASE2","title":"Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2026-02-01","conditions":"Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction","enrollment":""},{"nctId":"NCT04447118","phase":"PHASE3","title":"Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-11","conditions":"Non-squamous NSCLC, HER2 Exon 20 Mutation","enrollment":151},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT04034095","phase":"","title":"A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-08","conditions":"Prostatic Neoplasms","enrollment":979},{"nctId":"NCT03449901","phase":"PHASE2","title":"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-05-09","conditions":"Soft Tissue Sarcoma","enrollment":98},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":"Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":112},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT07257575","phase":"PHASE2","title":"A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-05","conditions":"Gastric Cancer Stage III","enrollment":138},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT07239271","phase":"PHASE3","title":"A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-16","conditions":"Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy","enrollment":2000},{"nctId":"NCT04854499","phase":"PHASE2","title":"Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":193},{"nctId":"NCT05057247","phase":"PHASE2","title":"Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC","status":"COMPLETED","sponsor":"Glenn J. Hanna","startDate":"2021-10-14","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer","enrollment":26},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03505320","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-29","conditions":"Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer","enrollment":143},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT03069937","phase":"PHASE2","title":"Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2017-03-01","conditions":"Metastatic Prostatic Adenocarcinoma","enrollment":52},{"nctId":"NCT06884254","phase":"PHASE3","title":"Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.","status":"WITHDRAWN","sponsor":"EirGenix, Inc.","startDate":"2025-05","conditions":"Early Breast Cancer","enrollment":""},{"nctId":"NCT04361708","phase":"PHASE1","title":"Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2020-05-08","conditions":"Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma","enrollment":54},{"nctId":"NCT05020457","phase":"PHASE2","title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-12-07","conditions":"Non Small Cell Lung Cancer","enrollment":69},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT06947291","phase":"PHASE2","title":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-06-04","conditions":"Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","enrollment":350},{"nctId":"NCT03340896","phase":"PHASE3","title":"Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-06-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":256},{"nctId":"NCT06874114","phase":"","title":"An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-02-28","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":700},{"nctId":"NCT05900206","phase":"PHASE2","title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-10-26","conditions":"Breast Cancer","enrollment":370},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT06902272","phase":"PHASE2","title":"ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-06-11","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07041788","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-07-10","conditions":"Cancer","enrollment":25},{"nctId":"NCT00076310","phase":"PHASE2","title":"OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-01-28","conditions":"Head and Neck Cancer","enrollment":50},{"nctId":"NCT07003074","phase":"PHASE3","title":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-06-23","conditions":"Breast Cancer","enrollment":642},{"nctId":"NCT06955702","phase":"NA","title":"Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients","status":"RECRUITING","sponsor":"University of Salamanca","startDate":"2023-11-15","conditions":"Breast Neoplasms, Alopecia, Madarosis","enrollment":120},{"nctId":"NCT02664935","phase":"PHASE2","title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-05","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma","enrollment":423},{"nctId":"NCT06861712","phase":"PHASE2","title":"Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-06","conditions":"Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)","enrollment":50},{"nctId":"NCT03161353","phase":"PHASE2","title":"Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2017-06-26","conditions":"Breast Cancer","enrollment":377},{"nctId":"NCT06935409","phase":"PHASE3","title":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-04-30","conditions":"Osteosarcoma","enrollment":117},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT02288247","phase":"PHASE3","title":"A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-12-01","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":688},{"nctId":"NCT04680442","phase":"PHASE2","title":"Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-01","conditions":"Breast Cancer, Heart Failure","enrollment":130},{"nctId":"NCT04256707","phase":"PHASE1, PHASE2","title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-01-14","conditions":"Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors","enrollment":126},{"nctId":"NCT06306612","phase":"NA","title":"CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-03-21","conditions":"Prostate Cancer","enrollment":192},{"nctId":"NCT00446225","phase":"PHASE3","title":"Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2007-02-15","conditions":"Non-Small Cell Lung Cancer","enrollment":174},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT05062980","phase":"PHASE1, PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer","status":"TERMINATED","sponsor":"Genprex, Inc.","startDate":"2022-03-30","conditions":"Non Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT06516887","phase":"PHASE1, PHASE2","title":"Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-12-27","conditions":"Advanced Lung Adenocarcinoma","enrollment":44},{"nctId":"NCT03317158","phase":"PHASE1, PHASE2","title":"Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder","status":"RECRUITING","sponsor":"Noah Hahn, M.D.","startDate":"2017-11-21","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":55},{"nctId":"NCT02182219","phase":"PHASE1","title":"Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11-01","conditions":"Prostatic Neoplasms","enrollment":21},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT03854227","phase":"PHASE1","title":"A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-03-14","conditions":"Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":54},{"nctId":"NCT04375605","phase":"PHASE3","title":"Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsmedizin Mannheim","startDate":"2020-06-03","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":342},{"nctId":"NCT06749886","phase":"PHASE2","title":"An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-11-19","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500},{"nctId":"NCT02578368","phase":"PHASE3","title":"Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2016-02","conditions":"Gastric Cancer","enrollment":183},{"nctId":"NCT04183062","phase":"PHASE2","title":"BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases","status":"WITHDRAWN","sponsor":"Nicklaus Children's Hospital f/k/a Miami Children's Hospital","startDate":"2019-10-04","conditions":"Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic","enrollment":""},{"nctId":"NCT06656624","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-13","conditions":"Advanced Breast Cancer","enrollment":190},{"nctId":"NCT00868491","phase":"PHASE2","title":"Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2008-03","conditions":"Head and Neck Cancer","enrollment":30},{"nctId":"NCT05156905","phase":"PHASE1","title":"Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2022-06-16","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":6},{"nctId":"NCT06618391","phase":"PHASE2","title":"Local Injection and Systemic Therapy in the Treatment of NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":84},{"nctId":"NCT06137378","phase":"PHASE2","title":"European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2024-04-17","conditions":"Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III","enrollment":140},{"nctId":"NCT02358473","phase":"PHASE1","title":"Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2015-01","conditions":"Non-Small Cell Lung Cancer","enrollment":13},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT00936936","phase":"PHASE2","title":"High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06-02","conditions":"Testicular Cancer","enrollment":64},{"nctId":"NCT01256359","phase":"PHASE2","title":"Docetaxel With or Without AZD6244 in Melanoma","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-10","conditions":"Melanoma","enrollment":83},{"nctId":"NCT03647969","phase":"PHASE2","title":"Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-11-07","conditions":"Adenocarcinoma of the Stomach, GastroEsophageal Cancer","enrollment":262},{"nctId":"NCT06542549","phase":"PHASE3","title":"Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-10-01","conditions":"Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Continuous Docetaxel","genericName":"Continuous Docetaxel","companyName":"University of Turin, Italy","companyId":"university-of-turin-italy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Continuous docetaxel is a taxane chemotherapy agent that stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}